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One of the most significant changes in the organisation of health care in the past two 
decades has been the increase in calls and attempts to involve users and publics in the 
processes of decision making. The application of forms of patient and public 
involvement (PPI) in health care decision making is seen to be able to make services 
and interventions more responsive to the needs of the patients and more aligned with 
public views on aspects of health care organisation such as priority setting. It is 
argued that PPI can address the ‘legitimacy problem’ of a wide range of health care 
institutions (1) but there is still little knowledge about the relationship between 
procedures, processes and outcomes of  PPI: who and how to involve, for what 
reasons, in which situations? 
Health technology assessment (HTA) is identified as a key domain in this arena 
because of how it underpins much of the knowledge and evidence that is brought to 
bear in health care decision making. Some researchers have advocated that patient-
focused HTA should reinforce the implementation of patient-centred care through the 
systematic evaluation of evidence on relevant preferences and views (2).  A recent 
literature review on patient and public involvement (PPI) on HTA processes found 
that patient and public representatives are mainly involved to provide evidence of 
needs and perspectives on the evaluation of technologies, but there is no systematic 
conceptualisation of the value and role of such contributions (3). An international 
survey of PPI practices found that, while there is evidence to suggest PPI procedures 
are widespread, HTA organisations are unclear about how to share knowledge about 
their activities and what the value of that knowledge is for other institutions (4).       
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These uncertainties are underpinned by a lack of theory regarding the knowledge and 
expertise brought by patient representatives and organisations to HTA processes. 
Presently, patients’ involvement in HTA is justified by the need to include 
‘experiential knowledge’ of living with and managing an illness in the evaluation of 
the clinical, social, and ethical effects of using a healthcare technology (5). Because 
illness experience varies across individual, social and cultural variables, there have 
been increased calls to systematise the integration of this type of knowledge by 
conducting primary or secondary research on patient perspectives  (6) (3). To a 
significant degree, these proposals aim to address the ambiguous status of individual 
patients’ perspectives both in HTA agencies and the social sciences, where some have 
argued that ‘experiential knowledge’ cannot be a robust base to evaluate the worth of 
research or technology (7).     
In this paper, I argue that research on patient involvement in HTA should shift from 
focusing on individual, embodied knowledge, derived from living with an illness, 
towards an understanding of knowledge as amassed and deployed by networks of 
variable complexity. Indeed, in Borkman’s original formulation of the concept of 
‘experiential knowledge’, expertise was derived from the collection, comparison and 
sorting of individual experiences in self-help groups; it was collectively produced and 
distributed across members of the group (8). Although such ‘experiential knowledge’ 
is usually seen in opposition to professional knowledge, particularly with the 
emergence of health social movements that specifically challenged established 
expertise from the 1960s (9), patient organisations have diversified the range of 
networks in which they participate (10) and expanded their repertoire of knowledge-
related activities, increasingly collaborating across expertise lines (11).  In our cross-
national, European study of patient organisations involvement in knowledge 
generation, dissemination and use, we have found that condition-focused 
organisations varyingly articulate the collection and shaping of experiential 
knowledge with credentialed knowledge, some of them becoming part and parcel of 
networks of established expertise (12). Publicly assuming this hybrid epistemic 
identity provides some patient organisations and their members with a capacity to 
intervene in and shape ‘evidence-based’ policy environments, including their 
participation in HTA research and forums, while others remain attached solely to their 
‘experiential knowledge’.  
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This paper aims thus to contribute to the understanding of the processes by which 
groups or citizens become involved in public issues around health technologies (13) 
(14) (15), by asking two related questions: a) What knowledge-related activities are 
patient organisations involved in?, and b) How are these knowledge activities related 
to the networks in which the patient organisation is embedded in? In the paper, I will 
address these questions by using the case of the Alzheimer’s Society (AS), the leading 
patient organisation for persons living with dementia and their carers in England and 
Wales. The case was integrated in the European study referred above and described in 
the Methods section, and is used in here because it represents an instance where high 
involvement in shaping research in HTA is associated with a strong historical 
integration in expert and policy network both nationally and globally. The relationship 
between involvement and network integration shapes the organisations’ epistemic 
identity:  how organisations construct their own role as knowledge producers; the 
value they ascribe to knowledge; and their understanding of the value and relationship 
between different types of knowledge. Below, I explore how the AS has actively 
transformed its epistemic identity by mobilising, extending and deepening 
collaborative links with clinicians, researchers and policy makers. This entailed 
questioning its sole reliance on ‘experiential knowledge’ as a basis to participate in 
the public shaping of dementia policy, and pursuing instead an identity that values the 
combination of experiential, clinical and scientific knowledge forms. In the 
Discussion, I will suggest that the case of the AS should be placed within a typology 
for patient and patient organisation involvement in HTA that could, with basis on 
more research, guide analysis and integration of users’ views in HTA. 
Methods 
A case-study is usually defined as a detailed exploration of a single event, process or 
setting. Recognised as a crucial methodology in the social sciences and as integral to 
social science reasoning (16), case study research aims to use cases to tease out and 
identify dimensions, conditions and relationships within social phenomena. As such, 
case-studies are also widely recognised for how they support the identification of 
previously ignored dimensions and relationships, having been the basis of key 
investigations in the history of the social sciences. Case studies provide an inductive 
understanding of complex causal links and of the conditions under which they might 
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be deployed. Case-studies may however suffer from selection bias where the choice 
of case is not explicitly articulated in relation to previous theory.   
The paper is based on research undertaken as part of a three-year international 
collaborative project entitled European Patient Organizations in Knowledge Society 
(EPOKS) which investigated patients’ organizations’ involvement in the production 
of knowledge through a variety of case studies across national contexts and condition 
areas. In the project, case studies provided an inductive understanding of complex 
links between activism, knowledge and networks and helped us identify dimensions, 
conditions and relationships that underpin different forms of activism. 
The data collected for each case study included: a) archival data relating to the history 
of each organisation, including extensive media archives, b) documentary data 
relating to the knowledge-related activities pursued by each organisation, c)   in-depth 
interviews with key actors within the organisation focusing on the role of knowledge 
and evidence in the activities and governance of the organisation, d) ethnographic 
observation of events –conference, campaign actions, etc – organised by the 
organisation.   
The analysis of the data for the case study presented in this paper followed an 
analytical induction approach, a species of case-based reasoning whereby instances 
are outlined and analysed in close and iterative relationship with the formulation of 
hypotheses (17). Three modules in this iterative process of analysis can be identified: 
a) initial analytical propositions were composed through constant comparison across 
data items; b) these propositions were further developed and stabilised in a ‘coding 
manual’; c) using the ‘coding manual’, data  was systematically coded, identifying 
deviant cases that enabled the revision and expansion of the coding manual. The 
analysis was further validated with triangulation across data sets collected in the 
project. 
The project was approved by the Ethics Committee of the School of Applied Social 
Sciences, Durham University, drawing on guidance from the Economic and Social 
Research Council and the European Commission. Due to the public profile of the 
interviewees, it was agreed that that they would not require anonymisation of 
transcripts but would have access to the final transcript used in analysis. All the other 
data collected was in the public domain.   
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Results 
In this section, I explore the dynamic relationship between the forms of knowledge 
assembled and deployed by one patient organisation and the networks of expertise and 
policy it mobilised to pursue its activities. I identify three phases of this dynamic in 
the history of the AS. In the first period, the AS established its epistemic identity 
around ‘caring knowledge’ by drawing on its volunteer membership, links with 
clinical specialists and support from the State. In a transition stage, the AS re-
articulated its identity as a combination of experiential, clinical and scientific 
knowledge in an attempt to redraw its relationship with volunteers and to expand its 
field of activism into HTA. In the most recent phase, the AS deepens and expands its 
network of associations to secure its role in the production of evidence that is brought 
to bear in health policy making.        
Becoming a carer organisation (1979-1999) 
Established in 1979 as the result of the cooperation between two former carers and 
two clinicians, the AS set its mission to be the provision of carer mutual support and 
of information on the relatively less known illness to members and the public. 
Supported by the newly established third-sector grants from the Department of Health 
and Social Services (DHSS), the AS quickly developed its care services into the mid-
1980s. In 1981, the ADS receives its first grant from the DHSS, which enables the 
appointment of the first Development Officer and for paying the running costs of a 
small office. This was key to its development in terms of branches and membership 
and its establishment in the public sphere, through features in the news and TV 
documentaries (e.g. ‘Suffer the Carers’, 1982). The growing reliance of the AS on 
government grants is attested by the fact that in 1985, DHSS grants accounted for 
85% of the income of the organisation. This supported further expansion, but also 
brought organisational uncertainties which were compounded by a 1987 audit on the 
DHSS which finds the AS accounting not to be within the ‘standards of accountancy’ 
(18).  This prompted a ‘major re-organisation’ (ADS Annual Report 1988) and 
streamlining of management between 1988 and 1991.              
The expansion of the volunteer-based structure of the organisation supported its 
growing awareness raising activities – the ‘Alzheimer’s Awareness Week’ - with 
targeted media interventions. This in turn fuelled the information providing role of the 
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organisation, particularly through its newly established public helpline, and its 
reliance on its ‘medical and scientific advisors’, who would ‘fill the gaps’ as they 
emerged through information requests (Interview Clive Evers, August 2009). The 
secure link with carers and volunteers was seen as a means to ‘produce political clout’ 
in a context where changes in the organisation of elderly care and social care were 
becoming more prominent in the UK. These factors worked together to make the AS 
an important stakeholder in social care policy, and in 1990 the organisation was a 
witness in House of Commons Enquiry on Social Services.   
By 1996, the AS had 470 staff, 413 of whom were employed in the provision of care 
services. Caring and ‘caring knowledge’ defined the public identity of the 
organisation: “we may not be able to offer the hope of a cure but we do offer unique 
understanding of caring issues, knowledge based on patient experience” (ADS 
Annual Report, 1996-97; my emphasis). This epistemic identity underpins a variety of 
campaigning activities around the re-organisation of community care services, the 
contribution of informal care to dementia management and consistent denunciations 
of the ‘health care lottery’ experience by users of dementia services in the NHS and 
social care. (The Times, April 1996. ADS Annual Report, 1997-98: p. 4). 
From carer to hybrid organisation (1999-2005) 
At the turn of the century, however, the AS, along with other organisations of the 
Alzheimer’s movement (19) took its first steps towards the integration of persons 
living with dementia (PWD) in the governance of the Society, its dementia services 
and information and research programmes. Publicly signalling this change, Harry 
Cayton, the AS  Director at the time, urged the newly formed National Institute of 
Clinical Excellence (NICE) to include the views of PWDs in the assessment of 
dementia drugs which had just been commissioned (Cayton, H. The Guardian, April 
2000). But this also represented a challenge to the blueprint of the organisation and to 
the society’s identity as a ‘carer’s organisation’. Further centralisation of management 
and discussions on how to ensure standardised quality of service across branches, set 
out in the One Society Programme in 2003, was interpreted by some within the 
Society as a challenge to the role of the volunteer (usually ex-carers) and to their 
experiential knowledge base. (Interview with Eileen Winston, London, 11 October 
2009; Rebellion at the Alzheimer’s Society’, The Guardian, 13 October 2004) 
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Aiming to solve these tensions, the AS had to re-define its epistemic identity. 
Whereas previously this was underpinned by ‘experiential knowledge’, by 2003, the 
AS fully endorsed an understanding of the organisation as assembling a ‘unique 
knowledge [that] brings together the expertise of carers with the skills and insights of 
health and social care professionals and the discoveries of scientific research’(Cayton, 
Cayton, ADS newsletter, August 1996: p. 2). Indicative of the epistemic hybridisation 
of the organisation, this identity became key in the integration of the AS in the 
debates about health technology assessment and the value of dementia drugs that were 
to affect the organisation in the years to come. In particular, it enabled the 
organisation to articulate and mobilise an extended network of actors that blurred 
expertise and membership boundaries. 
Reckoning networks (2005-2012) 
Between 2005 and 2007, the AS was involved in a major public controversy over 
access to dementia drugs on the National Health Service. The controversy was 
sparked when NICE suggested in 2005 that dementia drugs might be taken off NHS 
prescription packages on the basis of their cost-effectiveness value. From the start, the 
AS pointed towards the uncertainty of quality of life measurement in dementia that 
underpinned that evaluation, and attacked NICE’s focus on positive changes in 
cognitive scores as outcome measures.  Designing and conducting its own ‘research in 
the wild’ (20) in the form of a survey of their members, the AS argued that it was the 
maintenance of abilities and quality of life rather than cognitive enhancement that 
patients and carers valued.  
In parallel with their engagement with NICE, the AS mobilised to form a public 
campaign on the issue - The Action of Alzheimer’s Drugs Alliance – which 
comprised a heterogeneous set of institutions including Royal Colleges, universities, 
academic institutions and clinical centres. In October 2005, MPs from all parties 
passed an early motion in the House of Commons in which they ‘agree[d] with the 
Action on Alzheimer's Drugs Alliance that effective drug treatments for Alzheimer's 
disease should be available on the NHS and that NICE has failed to consider the 
important concerns […] about its draft guidance’.   
In view of this, NICE ordered a re-calculation of the available data and in January 
2006 published a new recommendation that cholinesterase inhibitors should be 
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available for patients with moderate dementia only. They had nevertheless still not 
taken into account the issue of quality of life measurement, which motivated the AS 
to join clinicians, researchers and manufacturers in appealing the decision. The 
appeals were rejected, and clinicians withdrew from the coalition of challengers, 
leaving the AS to join the judicial review put forward by manufacturers. Mainstream 
and professional publications suggested that, by challenging NICE’s methodology 
through the courts, the AS was undermining the regulator’s public legitimacy in 
favour of commercial agendas.     
In response to these losses and charges, the AS aimed to redefine its public identity by 
setting the agenda on national dementia strategy. This took the form of the 
commissioning and propagation of a series of expert reports on the state and future of 
dementia care, coordinated by sustained public demonstrations and political lobbying: 
the ‘Putting Care Right’ campaign (2007-2012). The start of the campaign was 
marked by the publication of the Dementia UK 2007 Report, where the AS sponsored 
credentialised experts to produce an assessment of the prevalence and economic cost 
of various types of dementia, and of levels of provision across the country. This 
exercise not only included the AS in the scientific effort to produce accurate estimates 
of the prevalence of dementia, but also, and importantly, endorsed the organisation’s 
capacity to speak for a group with specific needs in health and social care. Well linked 
into institutions of political representation, particularly Committees of House of 
Commons and Lords, the AS combined this political capital with the scientific 
authority of the report to be included in the negotiations that led to the establishment 
of the National Dementia Strategy in 2009 (21).   
Combining formal participation in these forums with public activism, the AS 
embarked on an assessment and critique of the state of dementia care in the UK 
through a series of campaign and lobbying actions focusing on care homes (2008), 
hospitals (2009) and community settings (2011). All campaigns were supported by 
reports using in-house quantitative research and a collection of personal accounts 
from carers and persons living with dementia. It is clear that the use of social research 
methodologies supported the AS’ aim to speak for ‘systemic issues’ in the 
organisation of dementia care, such as lack of specialised dementia care training, 
time-based tasking in care homes, etc. But of equal importance was AS’ use of 
personal accounts of experience of the issues. This combination exemplifies AS’ 
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attachment to a hybrid epistemic identity, where the quantification of factors leading 
to institutional failure gains relevance and depth when paired with exemplars of 
personal experience. 
However, the status of experience and experiential knowledge in the public activities 
of the AS was still an unresolved issue. Attributing the weakness of their arguments 
against NICE to the lack of methodological sophistication with which they had 
depicted the views of their members, from 2008, the AS linked with social scientists 
and other charities to produce, first a report on diagnosis and management of 
dementia from the perspective of PWDs (Dementia out of the Shadows) and then, 
crucially, two pieces of research about the issue of measurement of quality of life in 
dementia (My name is not Dementia). Of the latter, the first was a literature review 
conducted by experts at the University of Kent which identified an unduly  focus on 
health-related quality of life indicators in dementia research, particularly on cognition, 
and advocated the development of hybrid quality of life indicator that combine 
‘objective’ with ‘subjective’ domains of well-being (22).  
Such expert endorsement of the position of the AS in relation the use of quality of life 
measurement in HTA was complemented by mixed methods research used to gather 
the views of ‘seldom heard groups’ in quality of life in dementia research  (23). The 
research suggested that ‘people with dementia, even those with more severe dementia, 
do not automatically find their lives dominated by the condition itself and the impact 
that it has on their mental functioning’ (23). This directly challenged the assumptions 
of standardised quality of life measurement and academic quality of life research in 
dementia, but it was not aimed as a confrontation. Instead, the strategy of the AS was 
to publicly disclose key uncertainties in research on quality of life in dementia (24), 
and to align itself with a network of research and policy actors on the pursuing of a 
transformation of this field of research. This not only secured the AS’ place on the 
collective negotiation about research policy in dementia in the UK from 2010 
onwards, through its membership of the Ministerial Advisory Board Group on 
Dementia Research, but also enabled it to influence the attention given to ‘hybrid’ 
quality of life indicators within that forum and in the programme of dementia research 
sponsored by the National Institute of Health Research.  
Discussion 
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This case study report addresses a key issue in PPI in HTA and other instances of 
health policy making: how to conceptualise and understand the contribution of patient 
representatives and patient organisations in the generation and assessment of 
evidence? Current frameworks for integrating patients in HTA draw on the role of 
moral preferences and/or experiential knowledge in the clinical, social and ethical 
evaluation of health technologies (2). Often, however, this knowledge is 
conceptualised as embodied in individuals or articulated in their personal stories. This 
raises epistemological questions about the status of experiential knowledge in HTA. 
In this paper, I took as my point of departure the view that knowledge, including 
‘experiential knowledge’, is generated and deployed by networks (25), and that to 
understand one we have to understand the other. Drawing on comparative research on 
patients organisations in Europe, I have suggested that it is possible for patient 
organisations to re-formulate their epistemic identity so as to value and pursue the 
cross-linking between different forms of knowledge. As we have seen in the case of 
the AS, this is underpinned by a trajectory of mutual reinforcement between 
strengthening of networks and expansion of the epistemic repertoire of the 
organisation. This dynamic enabled the AS to publicly open core uncertainties in the 
measurement of quality of life in dementia and to actively shape the HTA research 
agenda on this issue. Importantly, it was because the AS explicitly investigated, in 
association with experts, through a variety of methodologies, the role of ‘experience’ 
in quality of life measurement that it was able to transform it into a matter of 
collective enquiry. Experiential knowledge became a part of the question, rather than 
the answer. 
As I have indicated, the exploration of the case of the AS is not intended as a 
guideline on how to involve patient organisations in HTA. Rather, it represents a case 
within a space of possible epistemic identities that patient organisations might deploy 
in their interaction with HTA agencies. Based on this case, it is hypothesised that 
patient organisations’ epistemic identity is a function of the relationship between 
knowledge activities and network integration. Knowledge activities can be ranked 
according to diversity, from single focus in one area – experiential knowledge or 
biomedical research – to diverse domains of engagement. Network integration relates 
to the strength and heterogeneity of links with other actors, which can be 
operationalized as robustness. This model predicts four different types of epistemic 
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identity for patient organisations (Figure 1): robust hybrid (A); weak hybrid (B); weak 
focused (C); and robust focused (D).  
Type A organisations are similar to the AS in its most recent phase of development, 
actively articulating their knowledge activities and their network alignment. 
Organisation of type B aim to diversify their knowledge engagement but show 
asymmetries in their ability to participate in some networks. They might, like the AS 
during its transition period, be locked into particular networks or unable to link 
effectively to others. Weak focused (C) organisations are those that invest in one type 
of knowledge – say, experiential knowledge - linked to one kind of network – 
members. Finally, robust focused organisations are those able to incorporate their 
specific, unique knowledge form as a key contribution to a wider process of 
knowledge making. This could be ‘experiential knowledge’ when this is used 
specifically in the re-making of expert knowledge about particular illnesses, for 
example. This typology, as most in the social sciences, is not intended a discrete, rigid 
classification of species of organisations but rather as a conceptual tool to understand 
the patient organisations’ epistemic identities, and their dynamic. 
HTA agencies and researchers wanting to integrate patient representatives and patient 
organisations in assessment processes could draw on this tool to make sense of the 
contribution they can make. Framing their possible contribution only in terms of 
‘perspectives’ and ‘experiential knowledge’ risks not only wasting relevant 
knowledge but also creating preventable conflict around PPI.  Moreover, using this 
model would underpin PPI in HTA on a sound theoretical basis that acknowledges the 
diversity of forms of engagement of patient organisations with knowledge making. 
This would mean relying less on the expert-lay boundary and delineate HTA as open-
membership ‘hybrid forums’ where experts, practitioners and patients collectively 
articulate the relationship between the evidence-base and contexts of use of 
technology (26, 27). 
A key limitation of the typological model presented here is that it is based on a single 
case study. As explained in the Methods section, the model was devised through the 
use of analytical induction and validated across the varieties of data set gathered for 
the project. This does not mean, however, that the model is proposed as a finished 
conceptual tool. It is indeed one of the features of analytical induction that models are 
proposed as working hypotheses. As a form of case-based reasoning, analytic 
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induction requires constant testing and conceptual development. The aim is not to use 
cases to confirm or reject theories, but to use them as resources for further conceptual 
exploration. It is my hope that readers of this paper will further test, expand and 
critique the model here proposed to gain a better understanding of patient involvement 
in the evaluation of health technologies. 
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Figure 1: Epistemic identity as function of the relationship between knowledge activities and network integration. 
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